Monday, March 30, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The Alarming Truth About Health Insurance Denials

Summary

In this episode of the Daily Remedy Podcast, the host discusses the alarming rates of health insurance claim denials, particularly under the Affordable Care Act. With statistics showing that one in five claims are denied, the conversation delves into the reasons behind these denials, including socioeconomic factors and the business model of insurance companies. The host argues that the high denial rates reflect a systemic issue within the industry, raising questions about consumer protection and potential fraud.

Takeaways

  • One out of every five claims made through ACA were denied.
  • UnitedHealthcare has the highest denial rate at 33%.
  • Socioeconomic status significantly impacts denial rates.
  • Patients with lower incomes face higher denial rates.
  • 54% of denied claims are eventually paid out.
  • Denials are a feature, not a bug, in health insurance.
  • 4.5 million claims were denied by Blue Cross Blue Shield of Alabama.
  • The denial rates indicate a systemic issue in the industry.
  • Health insurance companies may be committing fraud.
  • Consumer protection is crucial in addressing these issues.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!